An interventional study of Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s) and PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s)) in Ischemia, Myocardial, Coronary Artery Disease and Percutaneous Coronary Intervention (PCI), sponsored by Odense University Hospital. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Coronary Artery Disease by Odense University Hospital — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Odense University Hospital.
Among the 14 studies in Coronary Artery Disease by Odense University Hospital, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 14th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 14 studies in Coronary Artery Disease by Odense University Hospital is open now, in 1 country.
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,150 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 104 across the 11 interventional studies, 314 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Coronary Artery Disease by Odense University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
This study's planned enrollment of 3,150 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Myocardial Ischemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous coronary interventin with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent
Device: Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent)
Device: PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Number of patients with target lesion failure
Target lesion failure (TLF) is a composite of cardiac death, myocardial infarction (not clearly attributable to a non-intervention lesion) or target lesion revascularization with percutaneous coronary intervention or coronary artery bypass operation
Time frame: 1 year
Number of patients with all-cause death
All-cause death is defined as any death
Time frame: 1 year, 3 years and 5 years
Number of patients with cardiac death
Cardiac death is defined as death resulting from cardiovascular causes: death caused by acute myocardial infarction, death caused by sudden cardiac, including unwitnessed, death, death resulting from heart failure, death caused by cardiovascular procedures. Undetermined cause of death is defined as a death not attributable to any other category because of the absence of any relevant source documents. Such deaths will be classified as cardiovascular for end point determination
Time frame: 1 year, 3 years and 5 years
Number of patients with myocardial infarction
Myocardial infarction diagnosis follows "The Joint ESC/ACCF/AHA/WHF Task Force on "Third Universal Definition of acute myocardial infarction",which has been adapted by Academy Research Consortium. Acute myocardial infarction not related to other than index lesion is defined as any acute myocardial infarction that is not clearly attributable to a non-target vessel
Time frame: 1 year, 3 years and 5 years
Number of patients with definite stent thrombosis
Definite stent thrombosis is defined as: Angiographic confirmation of stent thrombosis. The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent or in a side branch originating from the stented segment and the presence of at least one of the following criteria: Acute onset of ischemic symptoms at rest New electrocardiographic changes suggestive of acute ischemia Typical rise and fall in cardiac biomarkers (refer to definition of spontaneous myocardial infarction) Or Pathological confirmation of stent thrombosis
Time frame: 1 year, 3 years and 5 years
Number of patients with probable stent thrombosis
Probable stent thrombosis is defined as any myocardial infarction that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause regardless of the time after the index procedure,
Time frame: 1 year, 3 years and 5 years
Number of patients with target lesion revascularization
Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment including the 5-mm margin proximal and distal to the stent
Time frame: 1 year, 3 years and 5 years
Number of patients with target vessel revascularization
Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel including the target lesion. The target vessel is defined as the entire major intervened coronary vessel, including side branches
Time frame: 1 year, 3 years and 5 years
Plan to share: Yes — IPD used in the results publication
Supporting information: Study protocol
Time frame: 12. NOV 2024 til the end of the study
Access criteria: On request
Data sharing details ↗ · www.clinicaltrials.gov
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jul 2028, 43 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 43 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.